The FDA on August 20, 2018 approved KEYTRUDA® in combination with ALIMTA® (Pemetrexed) and Platinum as first-line treatment of patients with metastatic, Non-Squamous Non-Small Cell Lung Cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. KEYTRUDA® is a product of Merck & Co., Inc.
Bottom Ad
Advertisement
Subscribe
